All In Biotech

Company

Denali Therapeutics Inc.

Drugs filed under this Drugs@FDA sponsor name, and trials whose lead sponsor matches it. The same company may file under other names.

Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

1

1 still marketed

Novel approvals

1

Approvals since 2021

1

Originals and new uses

Phase 3 trials

2

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

  • Avlayah approved NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanMar 24, 2026

Drugs in development (4)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline
  • DNL151BIIB122Phase 22 trials

    Denali Therapeutics Inc. · Parkinson Disease

  • DNL126Phase 21 trial

    Denali Therapeutics Inc. · Mucopolysaccharidosis Type IIIA

  • DNL593Phase 21 trial

    Denali Therapeutics Inc. · Frontotemporal Dementia

  • DNL952Phase 21 trial

    Denali Therapeutics Inc. · Late-onset Pompe Disease

Recruiting Phase 3 trials

Largest first.

No recruiting Phase 3 trials under this sponsor name.

Marketed drugs (1)

Newest FDA action first.

  • Avlayah Tividenofusp Alfa-Eknm · 2026

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.